By following this link you will be leaving a Takeda controlled website for a third party website
Please note that Takeda is not responsible or liable for any third party website and the website may not be appropriate for all audiences.
For adults with Chronic Idiopathic
Constipation (CIC)
Motegrity is a selective serotonin type 4 (5-HT4) receptor agonist.
Actor Portrayal
Offers simple dosing to work with your patients’ schedules.1
Once-daily dosing
Any time of the day
With or without food
It is important for patients to understand that Motegrity must be taken once daily as prescribed.1
Interested in receiving samples of Motegrity?
Your patients can benefit from a trial. Order a 7-day sample to get started.
2 mg
*Tablets shown are not actual size.
1 mg
*Tablets shown are not actual size.
Advise patients to:
Wondering which plans in your area cover Motegrity? See our patient access coverage tool to find out more.
Patient access coverage toolPlease expand for Indication and Important Safety Information.
Contraindications
Warnings and Precautions
Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.
Adverse Reactions
Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
Use in Specific Populations
INDICATION
Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Please click here for full Prescribing Information.
1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals America, Inc.